Related Experiment Videos
[Activated coagulation factors in various thrombotic diseases]
Y Komiyama1, T Murakami, M Masuda
1Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|December 1, 1995
Summary
Researchers developed a new assay for activated factor XI-alpha 1 antitrypsin complex (FXIa-alpha 1 AT) to detect hypercoagulable states. Elevated FXIa-alpha 1 AT levels indicate increased thrombotic risk in conditions like diabetes and coronary artery disease.
Area of Science:
- Biochemistry
- Hematology
- Clinical Diagnostics
Context:
- Thrombotic diseases are often associated with hemostatic abnormalities and hypercoagulable states.
- Previous assays have detected excess activation of coagulation factors like prothrombin, factor VII, factor IX, and factor XI.
Purpose:
- To develop and apply a novel enzyme-linked differential immunoassay for activated factor XI-alpha 1 antitrypsin complex (FXIa-alpha 1 AT).
- To evaluate the utility of FXIa-alpha 1 AT and thrombin-antithrombin III complex (TAT) assays in detecting hypercoagulable states in clinical samples.
Summary:
- The FXIa-alpha 1 AT assay detected increased plasma levels prior to Disseminated Intravascular Coagulation (DIC) onset.
- Elevated FXIa-alpha 1 AT and TAT levels were observed in patients with non-insulin-dependent diabetes mellitus, with FXIa-alpha 1 AT correlating with urinary albumin excretion severity.
- Significantly increased plasma FXIa-alpha 1 AT levels were found in patients with coronary artery disease, correlating positively with TAT, fibrinogen, and Lp(a).
Impact:
- The evaluation of activated coagulation factors provides valuable diagnostic information for thrombotic diseases.
- This assay offers a potential tool for early detection and risk stratification in patients with thrombotic conditions.
- Understanding hypercoagulability through markers like FXIa-alpha 1 AT can inform clinical management and therapeutic strategies.